RU2204609C2 - СПОСОБ ИДЕНТИФИКАЦИИ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С Е.Сoli, СПОСОБ РАЗВЕДЕНИЯ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С E.Coli, ВЫДЕЛЕННАЯ ДНК-МОЛЕКУЛА (ВАРИАНТЫ), МОЛЕКУЛЯРНЫЙ АНАЛИЗ ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 У СВИНЕЙ И НАБОР ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 - Google Patents
СПОСОБ ИДЕНТИФИКАЦИИ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С Е.Сoli, СПОСОБ РАЗВЕДЕНИЯ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С E.Coli, ВЫДЕЛЕННАЯ ДНК-МОЛЕКУЛА (ВАРИАНТЫ), МОЛЕКУЛЯРНЫЙ АНАЛИЗ ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 У СВИНЕЙ И НАБОР ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 Download PDFInfo
- Publication number
- RU2204609C2 RU2204609C2 RU99127287/13A RU99127287A RU2204609C2 RU 2204609 C2 RU2204609 C2 RU 2204609C2 RU 99127287/13 A RU99127287/13 A RU 99127287/13A RU 99127287 A RU99127287 A RU 99127287A RU 2204609 C2 RU2204609 C2 RU 2204609C2
- Authority
- RU
- Russia
- Prior art keywords
- pigs
- coli
- resistant
- diseases associated
- escherichia coli
- Prior art date
Links
- 241000282887 Suidae Species 0.000 title claims abstract description 112
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 55
- 108020004414 DNA Proteins 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 25
- 230000001488 breeding effect Effects 0.000 title claims abstract description 16
- 238000009395 breeding Methods 0.000 title claims abstract description 15
- 102000053602 DNA Human genes 0.000 title claims abstract description 10
- 208000028774 intestinal disease Diseases 0.000 title claims abstract description 9
- 238000007479 molecular analysis Methods 0.000 title claims abstract description 6
- 238000001514 detection method Methods 0.000 title abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 239000012472 biological sample Substances 0.000 claims abstract description 6
- 239000012634 fragment Substances 0.000 claims description 39
- 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 claims description 33
- 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 claims description 31
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 238000003752 polymerase chain reaction Methods 0.000 claims description 12
- 229930024421 Adenine Natural products 0.000 claims description 11
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 11
- 229960000643 adenine Drugs 0.000 claims description 11
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- 101150084750 1 gene Proteins 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 206010071602 Genetic polymorphism Diseases 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 34
- 108090000623 proteins and genes Proteins 0.000 abstract description 31
- 238000004458 analytical method Methods 0.000 abstract description 19
- 230000002068 genetic effect Effects 0.000 abstract description 11
- 238000002405 diagnostic procedure Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 1
- 108010079306 galactoside 2-alpha-L-fucosyltransferase Proteins 0.000 description 46
- 102100039835 Galactoside alpha-(1,2)-fucosyltransferase 1 Human genes 0.000 description 41
- 241000282898 Sus scrofa Species 0.000 description 30
- 108700028369 Alleles Proteins 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000035772 mutation Effects 0.000 description 18
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 15
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000000349 chromosome Anatomy 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 101001000966 Caenorhabditis elegans Galactoside 2-alpha-L-fucosyltransferase Proteins 0.000 description 10
- 244000144980 herd Species 0.000 description 10
- 210000000813 small intestine Anatomy 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 101150048676 FUT1 gene Proteins 0.000 description 8
- 241000255969 Pieris brassicae Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 102000054766 genetic haplotypes Human genes 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 101150010169 FUT2 gene Proteins 0.000 description 4
- 102000004913 RYR1 Human genes 0.000 description 4
- 108060007240 RYR1 Proteins 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000002497 edematous effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 101100227977 Sus scrofa FUT1 gene Proteins 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000031864 metaphase Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 241001076388 Fimbria Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010090763 Shiga Toxin 2 Proteins 0.000 description 2
- 230000010065 bacterial adhesion Effects 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 208000029182 enterotoxemia Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101100067450 Caenorhabditis elegans fut-2 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101100227969 Homo sapiens FUT1 gene Proteins 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- OXNGKCPRVRBHPO-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O OXNGKCPRVRBHPO-XLMUYGLTSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001224 bacterial fimbriae Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- -1 phenylalanine amino acid Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 102000042094 ryanodine receptor (TC 1.A.3.1) family Human genes 0.000 description 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 101150069452 z gene Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4718197P | 1997-05-20 | 1997-05-20 | |
| US60/047,181 | 1997-05-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU99127287A RU99127287A (ru) | 2002-08-10 |
| RU2204609C2 true RU2204609C2 (ru) | 2003-05-20 |
Family
ID=21947500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU99127287/13A RU2204609C2 (ru) | 1997-05-20 | 1998-05-20 | СПОСОБ ИДЕНТИФИКАЦИИ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С Е.Сoli, СПОСОБ РАЗВЕДЕНИЯ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С E.Coli, ВЫДЕЛЕННАЯ ДНК-МОЛЕКУЛА (ВАРИАНТЫ), МОЛЕКУЛЯРНЫЙ АНАЛИЗ ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 У СВИНЕЙ И НАБОР ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US6596923B1 (enExample) |
| EP (1) | EP0985052B1 (enExample) |
| JP (2) | JP3637420B2 (enExample) |
| CN (1) | CN1314953A (enExample) |
| AT (2) | ATE309392T1 (enExample) |
| AU (2) | AU7580798A (enExample) |
| BR (1) | BR9809137A (enExample) |
| CA (1) | CA2290768C (enExample) |
| CZ (1) | CZ298021B6 (enExample) |
| DE (3) | DE69832306T2 (enExample) |
| DK (2) | DK0985052T3 (enExample) |
| ES (2) | ES2203958T3 (enExample) |
| HK (1) | HK1040097A1 (enExample) |
| HU (1) | HUP0103587A3 (enExample) |
| MX (1) | MXPA99011988A (enExample) |
| NO (1) | NO996373L (enExample) |
| NZ (1) | NZ501886A (enExample) |
| PL (1) | PL195890B1 (enExample) |
| PT (1) | PT985052E (enExample) |
| RU (1) | RU2204609C2 (enExample) |
| WO (2) | WO1998053102A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2204609C2 (ru) * | 1997-05-20 | 2003-05-20 | Биотехнолоджи Резёрч Энд Девелопмент Корпорэйшен | СПОСОБ ИДЕНТИФИКАЦИИ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С Е.Сoli, СПОСОБ РАЗВЕДЕНИЯ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С E.Coli, ВЫДЕЛЕННАЯ ДНК-МОЛЕКУЛА (ВАРИАНТЫ), МОЛЕКУЛЯРНЫЙ АНАЛИЗ ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 У СВИНЕЙ И НАБОР ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 |
| US6355859B1 (en) * | 1997-05-20 | 2002-03-12 | Biotechnology Research And Development Corporation | Interactions between genotype and diet in swine that prevent E. coli associated intestinal disease |
| HU221664B1 (hu) * | 1999-03-31 | 2002-12-28 | MTA Állatorvostudományi Kutatóintézete | Élő, szájon át adható Escherichia coli vakcina készítésére alkalmas törzs a sertések választási hasmenésének megelőzésére és a törzs előállítására alkalmas eljárás |
| GB0118549D0 (en) * | 2001-07-30 | 2001-09-19 | Pig Improvement Uk Ltd | Methods |
| US7785778B2 (en) | 2002-11-25 | 2010-08-31 | University Of Copenhagen | Porcine polymorphisms and methods for detecting them |
| BR0317329A (pt) | 2002-12-31 | 2005-11-08 | Mmi Genomics Inc | Composições, métodos e sistemas para inferir traços bovinos |
| CN104982387B (zh) * | 2015-05-25 | 2018-01-23 | 广东温氏食品集团股份有限公司 | 一种muc13和fut1基因的分子标记辅助选择方法 |
| CN108348585B (zh) * | 2015-09-02 | 2023-12-15 | 杜邦营养生物科学有限公司 | 糖苷水解酶及其在预防和/或治疗动物中的病原体感染中的用途 |
| CN106480174B (zh) * | 2016-09-14 | 2019-04-16 | 扬州大学 | 一种用于猪抗病育种的遗传分子标记方法和应用 |
| CN108384865A (zh) * | 2018-02-07 | 2018-08-10 | 扬州大学 | Alpha菌毛基因在仔猪腹泻致病性大肠杆菌监测、鉴别中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625124A (en) * | 1994-07-11 | 1997-04-29 | Washington University | Animal model for helicobacter pylori infection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK41885A (da) | 1985-01-31 | 1986-11-13 | Slagteriernes Forskningsinst | 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen |
| EP0563144B2 (en) | 1990-12-21 | 2003-02-19 | The University Of Toronto Innovations Foundation | Diagnosis for porcine malignant hyperthermia |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5552144A (en) | 1992-01-22 | 1996-09-03 | Microcarb, Inc. | Immunogenic shiga-like toxin II variant mutants |
| AU5715194A (en) | 1992-12-04 | 1994-07-04 | N.V. Innogenetics S.A. | New polypeptides, nucleic acid sequences encoding them, and their use to prevent the adhesion of f107-fimbriated bacteria |
| WO1996028967A1 (en) | 1995-03-17 | 1996-09-26 | Chihiro Koike | Transgenic non-primatal mammals wherein serotypes of higher primates have been expressed by foreign gene transfer and method of creating the same |
| RU2204609C2 (ru) * | 1997-05-20 | 2003-05-20 | Биотехнолоджи Резёрч Энд Девелопмент Корпорэйшен | СПОСОБ ИДЕНТИФИКАЦИИ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С Е.Сoli, СПОСОБ РАЗВЕДЕНИЯ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С E.Coli, ВЫДЕЛЕННАЯ ДНК-МОЛЕКУЛА (ВАРИАНТЫ), МОЛЕКУЛЯРНЫЙ АНАЛИЗ ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 У СВИНЕЙ И НАБОР ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 |
| US6355859B1 (en) * | 1997-05-20 | 2002-03-12 | Biotechnology Research And Development Corporation | Interactions between genotype and diet in swine that prevent E. coli associated intestinal disease |
| US6569923B1 (en) * | 1999-03-19 | 2003-05-27 | John T. Slagter | Polymer-cement composites and methods of making same |
-
1998
- 1998-05-20 RU RU99127287/13A patent/RU2204609C2/ru not_active IP Right Cessation
- 1998-05-20 JP JP55057998A patent/JP3637420B2/ja not_active Expired - Fee Related
- 1998-05-20 HU HU0103587A patent/HUP0103587A3/hu unknown
- 1998-05-20 AT AT03001366T patent/ATE309392T1/de not_active IP Right Cessation
- 1998-05-20 HK HK02101688.3A patent/HK1040097A1/zh unknown
- 1998-05-20 DE DE69832306T patent/DE69832306T2/de not_active Expired - Fee Related
- 1998-05-20 CN CN98807387A patent/CN1314953A/zh active Pending
- 1998-05-20 MX MXPA99011988A patent/MXPA99011988A/es active IP Right Grant
- 1998-05-20 PT PT98923570T patent/PT985052E/pt unknown
- 1998-05-20 AU AU75807/98A patent/AU7580798A/en not_active Withdrawn
- 1998-05-20 CA CA002290768A patent/CA2290768C/en not_active Expired - Lifetime
- 1998-05-20 DK DK98923570T patent/DK0985052T3/da active
- 1998-05-20 WO PCT/US1998/010318 patent/WO1998053102A1/en not_active Ceased
- 1998-05-20 AU AU75832/98A patent/AU737862B2/en not_active Ceased
- 1998-05-20 EP EP98923570A patent/EP0985052B1/en not_active Expired - Lifetime
- 1998-05-20 WO PCT/US1998/010259 patent/WO1998053101A2/en not_active Ceased
- 1998-05-20 BR BR9809137-9A patent/BR9809137A/pt not_active Application Discontinuation
- 1998-05-20 ES ES98923570T patent/ES2203958T3/es not_active Expired - Lifetime
- 1998-05-20 ES ES03001366T patent/ES2248647T3/es not_active Expired - Lifetime
- 1998-05-20 PL PL98364701A patent/PL195890B1/pl unknown
- 1998-05-20 AT AT98923570T patent/ATE246731T1/de not_active IP Right Cessation
- 1998-05-20 CZ CZ0460799A patent/CZ298021B6/cs not_active IP Right Cessation
- 1998-05-20 NZ NZ501886A patent/NZ501886A/en unknown
- 1998-05-20 DE DE69816987T patent/DE69816987T2/de not_active Expired - Fee Related
- 1998-05-20 DE DE0985052T patent/DE985052T1/de active Pending
- 1998-05-20 DK DK03001366T patent/DK1310570T3/da active
-
1999
- 1999-11-19 US US09/443,766 patent/US6596923B1/en not_active Expired - Lifetime
- 1999-12-21 NO NO996373A patent/NO996373L/no unknown
-
2001
- 2001-04-27 US US09/844,705 patent/US6965022B2/en not_active Expired - Lifetime
- 2001-07-25 US US09/844,268 patent/US7193072B2/en not_active Expired - Fee Related
-
2004
- 2004-10-13 JP JP2004299458A patent/JP3941956B2/ja not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625124A (en) * | 1994-07-11 | 1997-04-29 | Washington University | Animal model for helicobacter pylori infection |
Non-Patent Citations (1)
| Title |
|---|
| COHNEY et al. Molecular cloning of the gene coding for pig alpha 1-->2 fucosyl transferase. - Immunogenetics, vol. 44, 1996, р.76-79. GAFFNEY et al. Effect of lewis blood group antigen expression on bacterial adherence to COS-1 cells. - Infection and Immunity, vol. 62, no. 7, 1994, р.3022-3026. VöGELI et al. Genes specifying receptors for F 18 fimbriated Escherichia coli, causing oedema disease and postweaning diarrhoca in pigs, мар to chromosome 6. - Animal genetics, vol. 27, 1996, р.321-328. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7785778B2 (en) | Porcine polymorphisms and methods for detecting them | |
| RU2204609C2 (ru) | СПОСОБ ИДЕНТИФИКАЦИИ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С Е.Сoli, СПОСОБ РАЗВЕДЕНИЯ СВИНЕЙ, РЕЗИСТЕНТНЫХ К КИШЕЧНЫМ ЗАБОЛЕВАНИЯМ, АССОЦИИРОВАННЫМ С E.Coli, ВЫДЕЛЕННАЯ ДНК-МОЛЕКУЛА (ВАРИАНТЫ), МОЛЕКУЛЯРНЫЙ АНАЛИЗ ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 У СВИНЕЙ И НАБОР ДЛЯ ОБНАРУЖЕНИЯ РЕЦЕПТОРОВ Е.Сoli F-18 | |
| US6355859B1 (en) | Interactions between genotype and diet in swine that prevent E. coli associated intestinal disease | |
| EP1310570B1 (en) | Methods and compositions to identify swine genetically resistant to F18 E. Coli associated diseases | |
| Cohney | HOSvyOrth et al. | |
| Ridpath et al. | HOSvyOrth et al. | |
| US6913885B2 (en) | Association of dopamine beta-hydroxylase polymorphisms with bipolar disorder | |
| Bosworth et al. | Interactions between genotype and diet in swine that prevent E. coli associated intestinal disease | |
| EP1561816A1 (en) | Methods for determining genetic resistance of pigs to diseases caused by rna viruses | |
| Janss et al. | Gene expression-phenotype associations using eQTL based gene sets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080521 |